Reimbursed Care Access in Jersey

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Jersey regulates controlled substances under the Misuse of Drugs (Jersey) Law and associated orders, which provide the legal framework for criminal liability and permitted medical/research exceptions #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, supply or production is criminalised under the Misuse of Drugs (Jersey) Law framework; any therapeutic access would be limited to formally approved clinical trials. #

Esketamine (Spravato®) is licensed in Europe/UK for certain indications in treatment‑resistant major depressive disorder (EC/MHRA approval lineage) and has specific specialist‑use and risk‑mitigation requirements (REMS / additional monitoring) as part of its marketing authorisation. Evidence of European/UK licensing and regulatory assessment is documented (European Commission / MHRA / EMA product information and UK guidance). #.

In the UK context NICE issued technology appraisal guidance (TA854) on esketamine for treatment‑resistant depression (TRD) and associated documents indicate that esketamine is not normally available on the NHS for TRD (NICE information for the public) and some NICE appraisals have led to restricted NHS availability on cost‑effectiveness grounds. This NHS/NICE position has direct bearing on small jurisdictions that look to UK reimbursement decisions when considering public funding: where NICE has not recommended routine NHS funding, routine public reimbursement in Jersey’s Health and Community Services would be unlikely without a specific Jersey funding decision. # #.

Practical access in Jersey: because esketamine is a licensed medicinal product in the wider UK/EU regulatory space, private clinics or specialist services could potentially arrange esketamine treatment subject to importation/medicines governance and supplier networks; however, there is no evidence of a Jersey public reimbursement pathway equivalent to an NHS national commissioning decision. Patients seeking esketamine in Jersey should expect private‑pay pathways or referral to authorised centres in the UK where local commissioning or private funding arrangements exist. (Regulatory/licensing sources cited above.)

Ketamine (racemic ketamine) is an established licensed anaesthetic and analgesic and is routinely available for medical use in hospitals in the UK/Channel Islands; it is also widely used off‑label in specialist psychiatric practice (intravenous infusions, intranasal and oral formulations) for treatment‑resistant depression and other conditions. The general medical/psychiatric use of ketamine is recognised in UK clinical services and guidance: ketamine is licensed as an anaesthetic agent while psychiatric applications are commonly off‑label and provided under clinician judgement and local governance. # # (legal/regulatory framework for controlled medicines in Jersey).

Reimbursement and access in Jersey: ketamine used for conventional (anaesthetic/analgesic) indications will be supplied and reimbursed through standard hospital medicines procurement and service billing under Jersey Health and Community Services formularies and budgets. For psychiatric (off‑label) ketamine treatment (e.g., IV infusion for TRD), access is typically provided through specialist services and often via private clinics or tertiary referrals; reimbursement depends on whether the treatment is commissioned by Jersey Health and Community Services or is delivered privately. There is no public, published Jersey policy explicitly funding off‑label ketamine for depression; therefore psychiatric ketamine is most commonly a private‑pay or individually commissioned service where demonstrated clinical need and case‑by‑case funding arrangements exist. Local medicines governance (Health and Community Services medicines information and formulary committees) would oversee any commissioned use. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and DMT‑containing preparations) are controlled under Jersey's misuse of drugs legislation; therapeutic access would be limited to formally approved clinical trials only. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is widely scheduled internationally and is treated as a controlled drug in jurisdictions that mirror UK/European/UN scheduling principles; in Jersey it falls under the Misuse of Drugs (Jersey) Law regime and is not available for routine medical use. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not authorised as a medicine in the UK and is treated as a controlled substance in most comparable jurisdictions; Jersey’s Misuse of Drugs (Jersey) Law covers prohibited substances and any therapeutic use would be restricted to approved clinical trials or specific authorised research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ayahuasca preparations contain DMT (a controlled substance), meaning possession, supply or use falls within the Misuse of Drugs (Jersey) Law controls; access for religious, ceremonial or therapeutic purposes is not authorised outside approved research or very narrow law‑enforced exceptions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and peyote/mescaline‑containing cacti are controlled under Jersey’s misuse of drugs framework; therapeutic or ceremonial access would require formal research authorisation. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C‑series phenethylamines (including 2C‑X variants) are illicit substances under UK/European/UN scheduling principles and are covered by Jersey's Misuse of Drugs (Jersey) Law criminal provisions; there is no routine medical or reimbursement pathway. #